- Home
- SOR vs CTNM Comparison
SOR vs CTNM Comparison
Compare SOR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SOR | CTNM |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.5M | 507.0M |
| IPO Year | 1995 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SOR | CTNM |
|---|---|---|
| Price | $47.22 | $13.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.80 |
| AVG Volume (30 Days) | 12.5K | ★ 174.8K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.66 | $3.35 |
| 52 Week High | $50.41 | $16.33 |
Technical Indicators
Market Signals| Indicator | SOR | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 42.36 |
| Support Level | $45.92 | $10.17 |
| Resistance Level | $50.05 | $16.17 |
| Average True Range (ATR) | 1.05 | 0.98 |
| MACD | -0.19 | -0.35 |
| Stochastic Oscillator | 37.93 | 11.18 |
Price Performance
Historical ComparisonAbout SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.